Suraksha Diagnostic Ltd

Suraksha Diagnostic Limited announced the appointment of Ms. Shreya Arora as Company Secretary & Compliance Officer, effective October 14, 2026, as approved by the company's board of directors at a meeting held on Wednesday, October 14, 2026. Ms. Arora is an Associate Member of the Institute of Company Secretaries of India (ICSI) and has over 12 years of experience in corporate secretarial functions, previously serving as Company Secretary and Legal Head at Kutchina Home Makers Private Limited.

Suraksha Diagnostic Limited, on October 5, 2026, submitted a certificate to the BSE Limited and the National Stock Exchange of India Limited, received from KFin Technologies Limited, the company’s Registrar and Share Transfer Agent, detailing securities dematerialized and rematerialized for the quarter ended September 30, 2026, in compliance with Regulation 74(5) of the SEBI (Depositaries and Participants) Regulations, 2018.

Suraksha Diagnostic Limited informed the BSE Limited and the National Stock Exchange of India Limited that the trading window for dealing in securities of the company will be closed for all designated persons and their immediate relatives from October 1, 2026, and will remain closed until 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026.

Suraksha Diagnostic Ltd share price declined by 2.86% to Rs 258.05. The Company's net profit saw a strong growth of 108.60% to Rs 12.85 crore, while revenue from operations improved marginally 7.66% to Rs 87.65 crore in Q2FY26 over Q1FY26. The market capitalization of Healthcare Service Provider industry group stocks on BSE stood at Rs 72411.07 crore, climbing 10.23%. It has inched up 2.96% over last one week and surged by 17.34% in last one month while the market capitalization of Suraksha Diagnostic Ltd has marginally improved by 7.64% and 10.58% in the same period respectively. Profit before tax (PBT) of Suraksha Diagnostic Ltd stood at Rs 16.53 crore in Q2 FY26, rallying 32.56% year-on-year, and surging by 65.63% quarter-on-quarter. EBITDA came in at Rs 29 crore, jumping 28.50% YoY and expanding by 24.47% sequentially. Total expenses posted a minor rise of 0.28% to Rs 68.49 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 10.0 crore, easing 1.57% YoY, while employee benefits expense was at Rs 14.41 crore, inching up 5.41% YoY. For the TTM ended FY26, revenue from operations grew 15.26% to Rs 252.09 crore, while net profit soared by 33.94% to Rs 30.98 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 6822% to Rs 77.39 crore, and PBT witnessed a strong rise of 31.67% to Rs 41.41 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 63.36 crore in FY26, as against Rs 60.48 crore in FY25. Suraksha Diagnostic Ltd tumbled by 13.11% in last one year, underperforming the benchmark BSE Sensex which has eased by 3.04% during the same period.

Suraksha Diagnostic Limited will hold a board meeting on Wednesday, August 12, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, according to a regulatory filing on August 4, 2026. The trading window for the company's securities, which was closed on July 1, 2026, will reopen 48 hours after the financial results are declared.

Suraksha Diagnostic announced that the 21th Annual General Meeting(AGM) of the company will be held on 2 September 2026.

Suraksha Diagnostic announced that the Board of Directors of the Company at its meeting held on 21 May 2026, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 25%) , subject to the approval of the shareholders.

Suraksha Diagnostic Ltd lost 7.95% today to trade at Rs 294.5. The BSE Healthcare index is down 0.51% to quote at 47612.76. The index is up 9.48 % over last one month. Among the other constituents of the index, Max Healthcare Institute Ltd decreased 5.18% and Aurobindo Pharma Ltd lost 3.54% on the day. The BSE Healthcare index went up 11.99 % over last one year compared to the 7.03% fall in benchmark SENSEX. Suraksha Diagnostic Ltd has added 4.27% over last one month compared to 9.48% gain in BSE Healthcare index and 4.15% drop in the SENSEX. On the BSE, 1019 shares were traded in the counter so far compared with average daily volumes of 3298 shares in the past one month. The stock hit a record high of Rs 353.65 on 26 Jun 2025. The stock hit a 52-week low of Rs 224.1 on 30 Mar 2026.Powered by Capital Market - Live

Net profit of Suraksha Diagnostic declined 15.02% to Rs 6.28 crore in the quarter ended March 2026 as against Rs 7.39 crore during the previous quarter ended March 2025. Sales rose 25.07% to Rs 81.41 crore in the quarter ended March 2026 as against Rs 65.09 crore during the previous quarter ended March 2025. For the full year,net profit rose 1.16% to Rs 32.19 crore in the year ended March 2026 as against Rs 31.82 crore during the previous year ended March 2025. Sales rose 23.13% to Rs 310.41 crore in the year ended March 2026 as against Rs 252.09 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales81.4165.09 25 310.41252.09 23 OPM %29.9229.47 -30.7332.23 - PBDT21.2417.94 18 86.0176.70 12 PBT9.989.21 8 44.5641.41 8 NP6.287.39 -15 32.1931.82 1 Powered by Capital Market - Live

Suraksha Diagnostic will hold a meeting of the Board of Directors of the Company on 21 May 2026.